A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial

Dougados, Maxime; Combe, Bernard; Braun, J.; Landewé, Robert; Sibilia, Jean; Cantagrel, Alain; Feydy, A.; Heijde, Desirée van der; Leblanc, Véronique; Logeart, I.

doi:10.1136/ard.2009.121533

Cited by 98 publications

(35 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…While there is no fully published study on the effect of etanercept on enthesitis in patients with PsA, the HEEL trial investigated etanercept in the treatment of refractory heel enthesitis in spondyloarthritis defined using the Amor criteria, which includes PsA [72]. In this small study, 24 patients were randomized to etanercept 50 mg once weekly (n = 12) or placebo (n = 12); stable concurrent DMARD doses were continued.…”

Section: Treatment Of Enthesitis In Psoriatic Arthritismentioning

confidence: 99%

Enthesitis in Psoriatic Disease

McGonagle

Helliwell²,

Veale³

2012

Dermatology

View full text Add to dashboard Cite

Enthesitis is increasingly recognized as an important component in psoriatic arthritis (PsA). Improved imaging techniques have expanded our understanding of the role of enthesitis in PsA and provided methods for earlier detection and assessment. Increased knowledge about the extent of tendon and ligament involvement has led to the theory that enthesitis may be the primary event in PsA. Given the historical difficulties in detecting and measuring enthesitis, its inclusion as an endpoint in PsA trials has been limited. Current trial data suggest that tumour necrosis factor inhibitors can successfully treat PsA-related enthesitis, which may have implications for the long-term prognosis of PsA. In this article, we review methods for detecting and assessing enthesitis, current thinking regarding the role of enthesitis in the pathogenesis of PsA, and trial evidence for the treatment of PsA and, therefore, enthesitis.

show abstract

Section: Treatment Of Enthesitis In Psoriatic Arthritismentioning

confidence: 99%

Enthesitis in Psoriatic Disease

McGonagle

Helliwell²,

Veale³

2012

Dermatology

View full text Add to dashboard Cite

show abstract

“…Anti-TNF therapy provides substantial symptom relief and has effects on many of the axial, peripheral and extra-articular features of AS. [29][30][31][32] However, while anti-TNF therapy reduces inflammation and prevents further joint destruction 33 it neither prevents nor slows bone formation. [34][35][36] Side effects of long-term anti-TNF therapy include increased susceptibility to tuberculosis infection due to systemic immune suppression.…”

Section: Treatmentmentioning

confidence: 99%

The genomics and genetics of ankylosing spondylitis

Kenna¹,

Davidson²,

Thomas³

2011

AGG

View full text Add to dashboard Cite

Abstract:The spondyloarthropathies are a group of arthritides which specifically target the spine and pelvis with ankylosing spondylitis (AS) being the most prevalent and debilitating of these conditions. Unique to AS is the progression to excessive uncontrolled bone formation following an initial inflammatory phase that can result in joint fusion and significant disability. Spondyloarthritis is estimated to affect 1%-2% of the population, twice as many as rheumatoid arthritis and thus constitutes a significant health problem. Currently AS pathogenesis is very poorly understood but recent large-scale genetics and gene expression profiling studies have identified some of the underlying mechanisms and pathways contributing to the disease. Genome-wide association studies have identified a number of candidate genes associated with AS sharing the same pathways which are now being targeted for therapeutic intervention. However, although such approaches can identify genes contributing to the disease process and are very informative as to disease aetiopathogenesis, they cannot profile the actual changes in gene/cell activity at any point in the disease process or possibly more importantly at specific sites. Such information is generated using expression profiling. A number of expression profiling studies have been undertaken in AS, looking at both circulating cells and tissues from affected joints. Although some common genes/pathways have been identified, overall the results to date have been somewhat disappointing due to differences in experimental design and tissue source as well as the low power of the studies. More recent better powered studies have shown some potential in developing gene expression profiling as a diagnostic tool in AS. True future success will rely on larger genetic and genomic studies and the combination of these datasets in eQTL studies requiring significant collaborative efforts. Such larger-scale approaches will also generate sufficient power to target specific disease stages and sites.

show abstract

“…При воспалительных заболеваниях кишечника необходи-мо использовать только моноклональные антитела (ИНФ, АДА, ГЛМ, ЦЗП), а при увеите их эффективность несколь-ко выше, чем у растворимых рецепторов (ЭТЦ). Однако при невозможности применения моноклональных антител к ФНОα у больных АС с увеитом ЭТЦ может быть адекват-ной заменой [20,21,[42][43][44]. В то же время при высоком риске активации туберкулезной инфекции назначение растворимых рецепторов более целесообразно.…”

Section: коксит (резистентный к лечению нпвп)unclassified

“…Хотя прямых сравнительных исследова-ний по эффективности разных иФНОα при АС не проводилось, сопоставление результа-тов контролируемых и когортных исследова-ний показало, что все препараты этой группы (ИНФ, АДА, ЭТЦ, ГЛМ, ЦЗП) обладают сходной эффективностью в отношении ос-новных проявлений заболевания (спондилит, артрит и энтезит) на разных стадиях заболева-ния [19][20][21][22]. Имеются данные об улучшении функциональных возможностей у больных АС даже при полном анкилозе позвоночника.…”

unclassified

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Lapshina¹,

Дубинина²,

Бадокин³

et al. 2016

rsp

View full text Add to dashboard Cite

The paper provides guidelines for the use of tumor necrosis factor-α (TNF-α) inhibitors in the treatment of patients with axial spondyloarthritis (axSpA), including ankylosing spondylitis. It gives data on the efficacy of TNF-α inhibitors in patients with non-radiographic axSpA. By using international and Russian guidelines, the authors lay down indications for this therapy and criteria for evaluation of its efficiency and safety. Key words: axial spondyloarthritis; ankylosing spondylitis; tumor necrosis factor-α (TNF-α) inhibitors; efficacy; safety. For reference: Lapshina SA, Dubinina TV, Badokin VV, et al. Tumor necrosis factor-α inhibitors in the treatment of axial spondyloarthritis, including ankylosing spondylitis.

show abstract

A randomised, multicentre, double-blind, placebo-controlled trial of etanercept in adults with refractory heel enthesitis in spondyloarthritis: the HEEL trial

Cited by 98 publications

References 21 publications

Enthesitis in Psoriatic Disease

Enthesitis in Psoriatic Disease

The genomics and genetics of ankylosing spondylitis

TUMOR NECROSIS FACTOR-α INHIBITORS IN THE TREATMENT OF AXIAL SPONDYLOARTHRITIS, INCLUDING ANKYLOSING SPONDYLITIS

Contact Info

Product

Resources

About